100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond
FDA Approves Taletrectinib Label Update With 49.7-Month Duration of Response in ROS1+ NSCLC
GSK Bets Up to $750M on Chimagen Trispecific T Cell Engager
Applications Open for the New Radiation Oncology Fellowship Programme - ESO
HARMONi-2 Shows Overall Survival Benefit With Ivonescimab Over Pembrolizumab in First-Line PD-L1–Positive NSCLC
Mosunetuzumab Plus Lenalidomide Improves PFS in Follicular Lymphoma in Phase 3 CELESTIMO Trial
Beyond Maximum Grade: Assessing Tolerability in Modern Hematologic Therapies
Jasmine Kamboj at COGC 2026: Let Us Build a Better Future of Oncology Together
